Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma

Rearrangements/fusions involving the anaplastic lymphocyte kinase (ALK) gene occur in 3% to 7% of non-small cell lung carcinoma (NSCLC) cases [1]. Various ALK fusion variants, including EML4, KIF5B, TFG, KLC1, among others, have been identified in NSCLC [2]. Here, we present a case of a novel ALK fusion partner, protein kinase C epsilon (PRKCE), in a patient with NSCLC who exhibited a positive response to the ALK inhibitor ensartinib.